Chapter 48. Management of Patients with Essential Thrombocythemia

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director4,5,
  2. Jeff Ginsberg MD, FRCPC Professor6,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor7,8,
  4. Ralph M. Meyer MD, FRCPC Director Professor9,10 and
  5. Richard Lottenberg MD, FACP Professor11
  1. Guido Finazzi MD Director1,
  2. Giovanni Barosi MD Director2 and
  3. Tiziano Barbui MD3

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch48

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Finazzi, G., Barosi, G. and Barbui, T. (2008) Management of Patients with Essential Thrombocythemia, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch48

Editor Information

  1. 4

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 5

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 6

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 7

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 8

    McMaster University, Hamilton, Canada

  6. 9

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 10

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 11

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. 1

    Transfusion Medicine and Haemostasis and Thrombosis Services, Ospedali Riuniti, Bergamo, Italy

  2. 2

    Unit of Epidemiology Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy

  3. 3

    Department of Hematology-Oncology, Ospedali Riuniti di Bergamo, Bergamo (Bg), Italy

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857



  • Essential thrombocythemia (ET) as amyeloproliferative disorder (MPD);
  • cytoreductive agents for patients with ET;
  • risk factors for thrombosis and bleeding in essential thrombocythemia;
  • treatment of choice;
  • patients with essential thrombocythemia;
  • antiplatelet therapy;
  • ET management in pregnancy and those of childbearing age;
  • low-dose aspirin for patients with microcirculatory symptoms


This chapter contains sections titled:

  • Introduction

  • Questions

  • Literature-search strategy and inclusion

  • When should cytoreductive agents be commenced for patients with ET?

  • What is the treatment of choice for those patients who require therapy?

  • Recommendations

  • When should antiplatelet therapy be used?

  • Recommendations

  • How should ET be managed in patients who are pregnant or of childbearing age?

  • Recommendations

  • References